Pharmaceutical Technology

APRIL 13, 2023

Takeda has announced that it will be pivoting away from its discovery and preclinical programmes in adeno-associated virus (AAV) gene therapies. Takeda’s announcement underlines the risk associated with gene therapy R&D at the preclinical stage and the fact that many current AAV programs are unlikely to reach late-stage trials.

Gene Therapy 243

Gene Therapy Marketing Gene In-Vivo 243

pharmaphorum

JANUARY 29, 2021

Genome editing is an exciting but still nascent field, and companies in the area face as many obstacles as they do opportunities. Sangamo CEO Sandy Macrae told us how his company is being cautious about the hype and finding ways to be financially viable in an emerging space. Zinc fingers. billion in funding.

Gene Editing 144

Gene Editing Gene Gene Therapy In-Vivo 144

Drug Discovery World

APRIL 3, 2023

From humble beginnings in the founder’s basement, UK-based Aptamer Group is now supplying its Optimer binders to clients across big pharma. DS: The company now has clients across big pharma. Our partnerships with big pharma have grown based on our detailed understanding of the science that underpins their specific challenges.

Antibody 52

Antibody Gene Therapy Gene In-Vitro 52

Drug Discovery World

SEPTEMBER 28, 2022

Its application in pharma, most commonly in drug discovery, has been steadily growing with global partnerships between tech vendors and pharma companies becoming more commonplace. According to Hampleton Patners’ latest Healthtech M&A market report2, digital health companies raised a total of $57.2

Pharma Companies 52

Pharma Companies Drugs In-Vivo Genetics 52

Drug Discovery World

NOVEMBER 16, 2022

DDW Editor Reece Armstrong learns about Molecular Devices’ Organoid Innovation Centre (OIC) and how the company is aiming to advance research into 3D biology and organoids. . Therefore, while researchers can understand just how a drug molecule impacts a cell, they can’t be sure that it will perform the same when used in-vivo. .

Drugs 97

Drugs In-Vivo In-Vitro Scientist 97

Drug Discovery World

FEBRUARY 2, 2024

Every company does their purification differently, every company does their sequencing slightly differently, every company does their assays slightly differently. It’s not fully standardised, so companies still do some boutique work. However, we’re still a couple of years early for general purpose AI in science.

In-Vivo 52

In-Vivo Compliance Drugs Pharma Companies 52

Pharmaceutical Technology

MAY 24, 2023

By Luisa Sterkel & Joana Loureiro , Tenthpin Consultants The promise and potential of cell and gene therapies (CGT) has emerged in the recent past and currently over 1.500 CGT are registered for clinical trials holding great hope for the treatment of challenging and uncurable diseases.

Clinical Trials 246

Clinical Trials Clinical Trials Gene Therapy Clinical Supply Chain 246